On the heels of his upcoming interim title shot, UFC middleweight Yoel Romero will be looking for some restitution from a supplement maker.
In early 2016, Romero was suspended for six months by USADA after he tested positive for the banned substance Ibutamoren following a split-decision win over Ronaldo Souza. Romero claimed that supplement was tainted, and when USADA tested a separate independent sample of the supplement in question, it found that to be the case.
Still, Romero was subject to the six-month ban. And now, two years after he first was informed of the violation, he is suing the supplement maker, Goldstar Performance Products, according to a report from Forbes.
Romero filed the suit in New Jersey Superior Court, the report said, in regards to the company’s Shred RX product, which Romero said he was using when he tested positive in December 2015 a few days after his win over Souza.
Romero, the complaint says, gave USADA a Shred RX capsule from the bottle he had been taking from, and it tested positive for Ibutamoren. When USADA purchased a separate bottle of the product for an additional test it, too, tested for Ibutamoren. That led USADA to reach the determination that Romero had taken a tainted supplement, since Ibutamoren was not listed as one of the Shred RX ingredients, and it caused his suspension to be only six months.
According to the report, Romero’s complaint in the suit says Goldstar Performance Products “failed to maintain the production facility,” and also that it knew the supplement was contaminated. This, the complain says, damaged his reputation and caused him to lose a shot at the middleweight title.
This past July, Romero (12-2 MMA, 8-1 UFC) suffered his first loss in the UFC when he dropped a decision to Robert Whittaker (19-4 MMA, 10-2 UFC) in an interim middleweight title fight at UFC 213. Whittaker went on to become the middleweight champ with the removal of the interim tag when Georges St-Pierre vacated the belt he won from Michael Bisping.
Whittaker was supposed to fight former champ Luke Rockhold (16-3 MMA, 6-2 UFC) in the UFC 221 main event Feb. 10 at Perth Arena in Perth, Australia, on pay-per-view. But this past week, he was ruled ineligible due to injuries, and Romero was elevated to the fight with Rockhold for another interim belt, despite coming off a loss.
Romero had been booked to fight David Branch at UFC on FOX 28 on Feb. 24 at Amway Center in Orlando, Fla., but now will have another crack at a title. A win presumably would get him an eventual rematch with Whittaker in a title unification fight.view original article >>
Kelvin Gastelum was disappointed when Yoel Romero was given an interim title shot vs. Luke Rockhold at UFC 221. read news >>
The co-main event for Saturday night's UFC Fight Night card in Belem, Brazil between John Dodson and Pedro Munhoz has been scrapped. Munhoz didn't make weight on Friday coming in at 140 pounds — four read news >>
UFC welterweight Jim Wallhead will have to sit out the first half of 2018, but it could’ve been worse. read news >>
UFC athlete Jim Wallhead accepted a nine-month sanction after testing positive for a prohibited substance from a contaminated supplement. read news >>
We’ve seen a sharp increase in the number of UFC interim title fights recently, and Yoel Romero has been a beneficiary. read news >>
Yoel Romero (12-2) got an opportunity to win the UFC's interim middleweight title seven months ago when he lost to Australian Robert Whittaker via unanimous decision at UFC 213. Now this Saturday in read news >>
Yoel Romero picked up a championship-caliber win on Saturday, but he won’t have a title to show for it. read news >>
Former UFC bantamweight Carls John de Tomas has accepted a one-year suspension from USADA and the California State Athletic Commission. read news >>
Yoel Romero doesn’t get the honor of calling himself UFC interim champion, but he did deliver a highlight-reel finish in Australia. read news >>
Yoel Romero was unable to win the interim UFC middleweight championship at UFC 221, but he'll likely still get the next shot at Robert Whittaker. read news >>